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Background: Mucopolysaccharidosis II (MPS II) is associated with a broad spectrum of chronic and progressive,
life-limiting symptoms. Idursulfase is approved for MPS II enzyme replacement therapy (ERT) in over 50 countries.
This retrospective study evaluated the MPS II burden, organization of clinical care, and effects of idursulfase treatment
on the disease in France.
Methods: MPS II patients who had received idursulfase ERT in the French healthcare system were enrolled. In
addition to clinician and patient questionnaires, the Clinical Global Impression-Improvement (CGI-I); Patient Global
Impression-Improvement (PGI-I); KIDSCREEN-27, and EuroQoL-5D for adult patients scales were used to assess
quality of life (QoL) and efficacy.
Results: Fifty-two patients were enrolled from 5 sites in France. The majority of patients (69.2%) presented a
severe MPS II phenotype with progressive neurocognitive impairment. Major impacts on QoL were apparent, with
at least 1 member of the family having to reorganize working hours (45.5%) or to stop working (22.7%).
KIDSCREEN-27 and EuroQoL-5D scale scores were well below those for referent (control) populations. Most families
(70.0%) experienced a diagnostic delay of at least 3 years after the initial observation of symptoms. The MPS II
diagnosis was often delivered without adequate sensitivity, psychological support, or comprehensive information
about the disease. The study population had received a mean of 3.8 ± 1.3 years ERT. Forty-four percent of patients
with the attenuated phenotype (without progressive neurocognitive impairment) showed symptom improvement
during both the first year (Period 1) and from the end of the first year of treatment to “the present” (Period 2), as
measured by CGI-I/PGI-I. 30.3% and 9.1% of severe patients experienced symptom improvement during Periods 1
and 2, respectively, while 63.6% and 51.5% displayed no change. The most common adverse reactions reported
were skin rash and other infusion-associated reactions.
Conclusions: MPS II adversely affects multiple domains of QoL for patients and families, requiring multiple
healthcare services and social aid programs. The majority of patients with either phenotype experienced either
improvement or stability in their symptoms during the first year of ERT, but this was clearly less so for patients
with the severe phenotype after the first year of treatment.
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Mucopolysaccharidosis II (MPS II), also called Hunter
syndrome, is a rare X-linked recessive lysosomal storage
disease caused by iduronate-2-sulfatase enzyme defi-
ciency, leading to accumulation of the glycosaminogly-
cans, heparan and dermatan sulfate. The abnormal
deposition of glycosaminoglycans results in dysfunction
of multiple organs and systems and causes a broad
spectrum of chronic and progressive, life-threatening
symptoms [1]. The presentation and progression of MPS
II is variable. Several studies have noted significant
differences between attenuated and more severe phe-
notypes in terms of age at diagnosis, age at death, and
disease manifestations. The severe phenotype is more
common, affecting about two-thirds of patients with
MPS II, and is characterized by progressive cognitive
impairment and developmental regression, with death
usually occurring in the second decade of life. Patients
with the attenuated phenotype have no severe cognitive
impairment [2], but commonly suffer from joint stiffness
and contractures, cardiac disease and respiratory infec-
tion, and may rarely display non-progressive cognitive
impairment.
Children with either phenotype generally appear
normal at birth. Young et al. noted that the average age
of onset of symptoms was 2.5 years of age for severe
patients and 4.3 years of age for attenuated patients; the
average age of death was 11.8 years and 21.7 years,
respectively [3]. Some patients with the attenuated form
may not experience symptoms until late childhood or
early adolescence and may have near normal life expect-
ancy, while others may experience significant morbidity
and disability, including mild to moderate learning diffi-
culties [2]. Indeed, the number and somatic manifes-
tations can vary widely among patients within either
phenotypic group, and the 2 phenotypes should be con-
sidered a continuum rather than 2 distinct groups. The
diverse symptoms and functional deficits associated with
MPS II may severely impair the quality of life (QoL) of
patients and their caregivers or families [4]. However,
the total burden of MPS II, including healthcare, social,
and economic domains, is not well studied.
Recombinant human idursulfase (Elaprase®, Shire,
Lexington, MA) is approved in over 50 countries for
treatment of patients with MPS II. Regulatory agencies
approved idursulfase as enzyme replacement therapy
(ERT), based on the results of a pivotal phase 2 and 3
randomised, double-blind, placebo-controlled clinical
trial in 96 patients with MPS II, all with the attenuated
phenotype, aged 5 to 31 years [5]. An expert panel has
stated that all previously diagnosed patients for whom
there is an expectation that ERT will alter the course of
somatic involvement should be candidates for treat-
ment, even if cognitive impairment is already evident[6]. The expert panel also emphasized the necessity of
timely, individualized treatment. Generally, ERT should
be offered to all patients older than 5 years with the
attenuated phenotype; however, recent studies in children
younger than 5 years showed that results were similar to
those from the pivotal trial [7,8]. The importance of early
intervention with ERT is supported by data from recent
studies [9]. A study from Poland showed that early
intervention of ERT may markedly slow or prevent
some irreversible manifestations of MPS II, including
coarse facial features, joint disease, and cardiac function
[10]. For patients with severe cognitive decline and
physical impairment, it is recommended that the decision
to initiate ERT (or not) be made by the treating physicians,
the institution’s ethics committee, and the patient’s family
[11]. In addition, the decision of whether to initiate ERT
must include consideration of the total burden of MPS II
and its treatment on QoL, including economic, occupa-
tional, and lifestyle factors, as well as clinical measures.
Objectives
The aims of this study were to evaluate the burden of
MPS II on the QoL of patients and families and on the
healthcare and social services system in France, to docu-
ment the organization and quality of clinical management
of MPS II, and to describe the effects of idursulfase ERT
on disease progression as perceived by clinicians and
patients.
Methods
A cross-sectional study design was used to collect
patient and physician information using questionnaires
and scales for a national sample of patients with MPS II
treated with idursulfase in France. Two periods were
evaluated: Period 1 started at baseline of initial idursul-
fase treatment and ended after 1 year of treatment;
Period 2 began at the end of the first year of idursulfase
treatment and extended to the present (time of study
evaluation), and was required to be >2 years. The dur-
ation of the data collection period for this study was
12 months from February 1, 2011 to 31 January 2012.
Subjects were requested to provide retrospective data
when necessary.
Patient population
Patients who had a confirmed diagnosis of MPS II, were
receiving or had received idursulfase, and were being
treated by the French healthcare system only were
enrolled. Eligible patients were identified by the special-
ized French Reference Centers for Inherited Metabolic
Disease and Lysosomal Diseases. Those judged eligible
were mailed invitations to participate and were sent
follow up reminders if no response was obtained after
the first mailing. Patients/caregivers who accepted the
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consent for their medical data to be used anonymously
(written consent for patients aged 18 years and older,
written consent of at least one of the parents for pa-
tients younger than 18 years or adult patients with severe
cognitive impairment, or by his/her legal representative)
for inclusion in the study in conformance with the provi-
sions of the Commission Nationale de L’Informatique
et des Libertés. Because this study was observational in
design, and did not involve medical intervention (beyond
the usual treatment received by the patients) or physical
or psychological examination, it was not subject to the
provisions of the Comité de Protection des Personnes. The
investigators did not receive compensation for their par-
ticipation in the study.
Definitions of phenotypes
For the purposes of this study, patients were categorized
by the 2 phenotypes of MPS II, severe (with progressive
neurocognitive impairment) and attenuated (without pro-
gressive cognitive impairment), defined as follows:
 Severe phenotype—with neurocognitive regression
(most frequent). The first symptoms usually occur
during the first year of life and gradually increases
before the age of 2–3 years, with symptoms
including coarse facial features, enlarged liver and
spleen, stiff joints and contractures, dysostosis
multiplex, upper airway obstruction, hearing loss,
cardiac valve disease, and profound, progressive
neurological involvement. Death usually occurs in
the second decade of life.
 Attenuated phenotype—mild mental retardation
may be present, but without cognitive decline. The
attenuated forms of MPS II manifest in a wide variety
of ways. The symptoms are usually less marked than
the severe phenotype, and they usually appear later
in childhood or adolescence. Despite the absence
of cognitive impairment; somatic symptoms such as
hearing loss, glaucoma, retinopathy, dysostosis
multiplex, carpal tunnel syndrome, spine compression,
valvulo- and cardiomyopathy, upper respiratory
tract dysfunction, respiratory insufficiency,
hepatosplenomegaly, chronic diarrhoea, and short
stature, are common. Patients may live until
adulthood [2,12].
Study questionnaires and scales
Clinician and patient questionnaires were administered
at baseline, following enrollment of eligible patients, to
gather demographic and disease data on patients, as well
as information on the experience of patients and their
families of their treatment, and how they cope with the
burdens of the disease. Note that the questionnairesasked respondents to recollect current and historical
data. The clinician questionnaires included: MPS II
history, including date of diagnosis, specialty and setting
of physician who made the diagnosis, date of first symp-
toms, family history of the disease; clinical characteris-
tics of MPS II, including body systems affected and severe
events documented; criteria used to determine patient
eligibility for treatment; treatment history, including
onset, dose and frequency of idursulfase treatment and
method of administration (peripheral intravenous, or
central vein catheter); frequency of medical consulta-
tions; and the roles of the reference center and second-
ary center for follow up procedures. Items addressed in
the patient questionnaire included the circumstances of
the first observation of MPS II signs and symptoms; the
time from the observation of first signs to formal diag-
nosis; circumstances of the MPS II diagnosis; names
and locations of the reference and secondary treatment
centers; the distances between the patient’s home and
the reference and secondary centers; modes of transpor-
tation used by the patient to reach the center where
idursulfase was administered; level of transport cover-
age; and affiliation to patient associations and their role.
In addition to the clinician and patient questionnaires,
the following 4 instruments for measurement of QoL
and the effects of idursulfase treatment were used:
 The Clinical Global Impression-Improvement (CGI-I)
and Patient Global Impression-Improvement (PGI-I)
are scales that require the clinician (CGI-I) or the
patient/caregiver (PGI-I) to assess whether and how
much the patient’s illness has improved or worsened
relative to a baseline state at the beginning of the
treatment or time period with a choice of 7
responses: very much improved, much improved,
minimally improved, no change, minimally worse,
much worse, or very much worse [13]. The CGI-I
and PGI-I were measured for 2 periods. Period 1
compared patient status at baseline or before the
initiation of idursulfase treatment with that 1 year
later. Period 2 compared the patient’s status at 1 year
after the start of idursulfase ERT with the present;
Period 2 was required to be greater than 2 years
in duration. For all CGI-I and PGI-I evaluations,
respondents were asked to give ratings irrespective
of whether they thought any change was due to the
drug treatment.
 KIDSCREEN-27: This instrument is designed to
assess children’s and adolescent’s subjective health
and well-being in 5 dimensions: physical well-being
(5 items), psychological well-being (7 items), autonomy
and relationship with parents (7 items), social support
(4 items), and school environment (4 items). These
instruments were developed as self-reporting
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children and adolescents, ages 8 to 18 years [14-17].
 EuroQoL-5D-3L (EQ-5D): This is a standardised
instrument for use as a measure of health outcomes
and comprises 5 dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression,
each with 3 response levels: no problems, some
problems, and unable to/extreme problems [18].
The patients were also asked to rate their response
for each dimension on a vertical visual analogue
scale (VAS) of 0 (Worst imaginable health state) to
100 (Best imaginable health state).
The instruments used in the study were targeted for
specific age groups. For patients less than 8 years of age,
the PGI-I family and KIDSCREEN-27 were used; for
those aged 8 to 18 years and considered incapable, the
PGI-I family and the KIDSCREEN-27 family versions
were used. For those 8 to 18 years who were consid-
ered capable, the PGI-I family version and self-rated
KIDSCREEN-27 were used. For patients over 18 years,
the PGI-I self-rated questionnaire and EQ-5D were
used. Scores of KIDSCREEN-27 and EQ-5D were com-
pared with those of reference (control) respondents in
a general population of the same age and sex.
Statistical methods
Descriptive statistics were used for qualitative and ordinal
variables in terms of total numbers and frequency of each
condition; quantitative variables were described in terms
of number of responses, mean, standard deviation, mini-
mum, maximum, and median. For comparative analysis of
qualitative variables, the Pearson chi-square test was
applied except when the theoretical total numbers were
less than 5, in which case, the Yates’ continuity correction
or Fisher’s exact test was used. For quantitative variables,
Student t tests or variance analysis were used.
Results
Patient population
A total of 62 eligible patients with MPS II who had re-
ceived, or were currently receiving, idursulfase treatment
were identified at 6 French reference centers. Of this total,
10 eligible patients were not enrolled. Four patients were
not approached because of the state of their health, and 2
were not approached due to their social circumstances.
Four patients who were approached did not consent, al-
though the reasons for this are not known. The remaining
52 patients at 5 reference centers who accepted the invita-
tion were enrolled in the study. The patients were all
males and the great majority (84.4%) of patients were mi-
nors, and 48 (92.3%) were living with their parents.
Completed questionnaires were obtained from 51 (98.1%)
patients for the clinical section and family interview,33 (63.5%) answered the QoL questionnaires, including
26 (50.0%) who responded to the KIDSCREEN-27 scale
(5 child, and 21 parent versions), and 7 (13.5%) who
completed the EQ-5D scale (5 for the self-rated versions,
and 2 parent versions).
Demographic and clinical characteristics of study population
Characteristics of the study population are presented in
Table 1. The mean (SD) age was 12.4 ± 9.2 years (range
1 year to 51 years), and most patients were aged between
5 and 15 years. A family history of MPS II was present
in 17 (32.7%) patients, while 31 (59.6%) respondents re-
ported no family history of MPS II, and 4 (7.7%) said
that they did not know. Prenatal diagnosis had been per-
formed for only 1 patient.
Of the 52 patients, 36 (69.2%) were considered to have
the severe phenotype with cerebral involvement and 16
(30.8%) had the attenuated form, based on their physi-
cian’s diagnosis. The MPS-associated medical conditions
and surgical interventions reported among all patients
and within each phenotype are shown in Table 2. The
most common medical conditions for all patients were:
hearing loss (41 out of 51 respondents, 78.8%); disabling
joint stiffness (40/52, 76.9%); and hernia (37/52, 71.2%).
About 81% (42/52) of all patients, and similar proportions
of severe and attenuated patients (30/36 and 12/16, re-
spectively) had experienced at least 1 surgical intervention,
the most common being ear ventilation tubes (20/42
[47.6%] total; 13/30 [43.3%] severe, 7/12 [58.3%] attenu-
ated). Four (25.0%) attenuated patients had experienced
mild mental disability without cognitive decline.
Medical service needs
Hospital, medical, and paramedical consultations re-
ceived during the past 12 months of the study are shown
in Table 3. Of 51 respondents, 26 (51.0%) had been ad-
mitted to hospital because of their MPS II disease, with
a mean length of stay of 10.4 days (range 1–120 days).
Thirteen (25.5%) patients had visited the emergency
room a mean number of 2 times due to MPS II during
the previous 12 months, most commonly for respiratory
symptoms (6/13, 46.2%). The medical specialists visited
in the past year by the greatest number of patients were
dentists (22/51, 43.1%); ear, nose, and throat specialists
(25/51, 49.0%); and ophthalmologists (15/51, 29.4%).
Clinical Management
MPS II diagnosis
Among the 44 patients for whom diagnosis data were
available, the mean age at diagnosis was 3.5 ± 2.7 years,
ranging from < 1 year of age for 4 (9.1%) patients to
10 years and over for 3 (6.8%) patients. As noted above,
although a family history of MPS II was ultimately found
to be present in 17/52 (32.7%) of patients, prenatal
Table 1 Patient demographic and clinical characteristics
Characteristic All patients (N = 52)
Gender
Male 52
Age, ya
Mean (SD) 12.4 (9.2)
Median (min, max) 11.0 (1.3, 51.0)
Age, y, category, n (%)a
<2 1 (2.0)
2-5 5 (9.8)
5-10 17 (33.3)
10-15 16 (31.4)
15-18 4 (7.8)
18-29 4 (7.8)
≥30 4 (7.8)
Age at diagnosis, Mean (SD) 3.5 (2.7)
Years since diagnosis, y (n = 47)b
Mean (SD) 9.3 (8.4)
Median (min, max) 6.8 (0.7, 46.9)
Severe patients
Mean (SD) 6.7 (5.4)
Median (min, max) 5.2 (0.7, 27.5)
Attenuated patients
Mean (SD) 14.3 (11.0)
Median (min, max) 11.9 (1.7, 46.9)
Family history of MPS II
Yes 17 (32.7)
If yes, prenatal diagnosis 1 (5.9)
No 31 (59.6)
Do not know 4 (7.7)
MPS II Classification, n (%)c
Severe (with cognitive impairment) 36 (69.2)
Attenuated (without cognitive impairment) 16 (30.8)
Living Situation, n (%)
Living with parents 48 (92.3)
Living alone 3 (5.8)
Living in an institution during the week 1 (1.9)
aData missing for 1 patient.
bData missing for 5 severe phenotype patients.
cEstimates of the relative prevalence of each MPS II phenotype at any point in
time are affected by the higher mortality rates for severe versus attenuated
patients, and may vary substantially.
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of the time of the study, the mean time since diagnosis
was 9.3 ± 8.4 years. There was a substantial disparity in
the mean time since diagnosis among severe patients
(6.7 years) versus attenuated patients (14.3 years): twice
as long for attenuated compared with severe patients, aswould be expected based on the contrasting life expect-
ancy in the 2 groups.
The first MPS II symptoms occurred before the age of
1 year in most MPS II patients and at a mean age of 2.0
± 2.3 years. The first symptoms leading to suspicion of
MPS II were observed by parents or child for 25 (49.0%)
of the 51 respondents. In 7 (13.7%) instances, the treat-
ing paediatrician or family doctor first suspected the
condition, and for 6 (11.8%) patients, identification
occurred incidentally during a medical consultation or
hospitalisation. Five patients were initially suspected to
have MPS II because a family history of MPS II had been
documented, and 6 were identified by the school phys-
ician or speech therapist. Among 47 patients responding,
the time from observation/documentation of the initial
symptoms to formal diagnosis of MPS II (or diagnosis
delay) was less than 3 years for 10 (21.3%) patients, 3 to
7 years for 14 (29.8%), and from 7 to 20 years for 19
(40.4%) patients. While the majority 29/47 (61.7%) were
diagnosed within 9 years from the first appearance of
symptoms, 3/47 patients were diagnosed after 20 to
45 years, and 1 patient waited more than 45 years for
diagnosis. The largest proportion of patients (22/51,
43.1%) had to see 2 to 4 physicians before the diagnosis
was made, while one-third (17/51) saw only 1 physician,
and 9 patients consulted with 5 to 8 physicians before
receiving their final diagnosis. With regard to the man-
ner and sensitivity of the delivery of the final diagnosis,
20 (40.0%) out of the 50 respondents felt the diagnosis
was delivered in a brusque fashion, 17 reported the
delivery was tactful, and 13 said it was given with no
special consideration. Psychological support was sug-
gested following the delivery of diagnosis to only 14/49
(28.6%) respondents, while the majority (40/50, 72.0%)
received no such recommendation or referral. Only half
of the 50 respondents reported that they had received
clear information about the condition, and a minority
(19/50) described the information given as “sufficient”.
Place of idursulfase treatment
Idursulfase treatment took place in several locations. For
the 51 patients with data, 32 (62.7%) were treated at a
nearby hospital or infusion center, 13 (25.5%) at regional
specialised centers for rare diseases (“Centres de Com-
pétence”), and 4 (7.8%) patients were treated at home
(1 patient given home nursing care and 3 given hospital
care at home) under the Hospitalisation à Domicile
(HAD) program. Two patients discontinued treatment
because it was considered to be ineffective (the patient’s
condition worsened).
Treatment regimen
The mean total time of idursulfase treatment, incorpor-
ating both periods (from baseline of initial treatment
Table 2 Serious MPS II disease manifestations and concomitant medical issues for the patients in the study by
phenotype
Disease manifestationa, n (%) Severe (n = 36) Attenuated (n = 16) Total (N = 52)
Hearing loss 28 (75.7) 13 (86.7) 41 (78.8)
Disabling joint stiffness 25 (69.4) 15 (93.8) 40 (76.9)
Hernias 24 (66.7) 13 (81.3) 37 (71.2)
Adenoidectomy 22 (61.1) 13 (81.3) 38 (67.3)
Mental retardation 24 (66.7) 4 (25.0) 28 (53.8)
Spine deformities 17 (45.9) 9 (60.0) 26 (50.0)
Tonsillectomy 16 (44.4) 9 (56.3) 25 (48.1)
Recurrent otitis 17 (45.9) 7 (46.7) 24 (46.2)
Loss of vision 11 (30.6) 8 (50.0) 19 (36.5)
Sleep apnoea 13 (36.1) 5 (31.3) 18 (34.6)
Skin involvement 11 (30.6) 4 (25.0) 15 (28.8)
Other serious clinical eventsb 10 (27.0) 3 (20.0) 13 (25.0)
Breathing difficulties with hospitalisation 9 (25.0) 4 (25.0) 13 (25.0)
Stay in intensive care unitc 5 (13.9) 3 (18.8) 8 (15.4)
Aspiration requiring hospitalisation 2 (5.6) 1 (6.3) 3 (5.8)
Spinal cord compression 1 (2.7) 1 (6.3) 2 (3.8)
Heart failure with hospitalisation 1 (2.7) 1 (6.7) 2 (3.8)
aCounts are not mutually exclusive, patients can have more than 1 manifestation.
bBehavioural problems (6), asthma (1), epilepsy (1), psoriasis (1), accelerated growth (1), Prader-Willi syndrome (1), mitral valve dysplasia (1).
c1 post-operatively, and 1 for breathing problems.
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the median total time was 4.3 (range 0.5–7.3) years. The
mean idursulfase dose was 0.6 ± 0.2 mg/kg, and the
frequency of infusion was once per week in 50 (96.2%)
patients. The mean time of infusion per treatment was
2.3 ± 0.6 hours.
Home versus hospital treatment
When asked if they would prefer treatment at home
under HAD, 30 (63.8%) of 47 respondents responded “yes”;
the others responded “no” or “undecided”. Twenty-six of
the 37 respondents who marked “yes” or “undecided” and
responded to the follow up question thought that home
administration would benefit them because it is more com-
fortable for the patient to stay in their own environment,
and 23 said it eliminated the need to go to the hospital
every week. Eleven respondents of the 15 who wrote
“no” or “undecided” reported that they found hospital
care reassuring, 6 said they wanted to avoid having their
home become more like a hospital, and 4 felt that medical
monitoring of infusion was important. Other objections
expressed to home treatment included difficulty adapting
the home for the service, the belief that socialization to
hospital conditions was important, or that the hospital
was better able to help control a child’s agitation.
All of the 4 patients, 2 adult patients and 2 families
with their children, who were at the time having their
treatment administered by the HAD program, reportedsatisfaction with the organization and conduct of their
care. When asked for the reason for their satisfaction, 3
respondents said they preferred to stay in their own
environment, and 2 said that it saved them from travelling,
2 each stated that it made for better family arrangements
and eliminated the need to go to hospital for treatment,
and 1 reported that it saved time.
Impact of MPS II on quality of life
MPS II had a distinct impact on various aspects of QoL
and living arrangements for families. With regard to
work, among 44 respondents, 20 (45.5%) had to reorgan-
ize their working hours to attend to patient care, and 10
(22.7%) reported that 1 of the 2 parents had to stop
working, 4 (9.1%) had to change work, 1 had to take
repeated time off from work, and 1 had to take parent
leave. Mothers were far more frequently affected in their
working life than fathers (37 versus 5, respectively). Of
the 7 patients who were of working age, 3 had never
worked because of their long-term illness, 2 were work-
ing part time, 1 worked irregularly/casually, and 1 was at
college and lived in a special needs medical/educational
facility.
MPS II also affected place of residence for 4 of 51
families, with treatment considerations taking prece-
dence over other preferences, and necessitating a return
to France from abroad in 1 case. Of the 51 respondents, 8
(15.7%) had paid home help, at an average duration of
Table 3 Hospital, medical and paramedical visits/
consultations related to MPS II during the past
12 months (N = 51)
Hospital visits n (%) Mean (SD) visits/y
Emergency Room Visits 13 (25.5) 2.0 (1.3)
Respiratory problems 6 (46.2)
Abdominal pain/diarrhoea 2 (15.4)
Ear infection 2 (15.4)
Fever 2 (15.4)
Chest pain 1 (7.7)
Septic shock 1 (7.7)
Admitted to hospital 26 (51.0) 1.3 (0.8)
Duration of stay (days) 10.4 (25.3)
Medical specialty n (%) Mean (SD) Visits/y
Dentist 22 (43.1) 4.3 (6.4)
Ear, nose, and throat 25 (49.0) 11.2 (22.0)
Ophthalmologist 15 (29.4) 1.5 (1.6)
Orthopaedic surgeona 14 (29.8) 2.7 (2.5)
Other specialist 16 (31.4)
Dermatologist 5 (9.8)
Pneumonologist 4 (7.8)
Cardiologist 4 (5.9)
Allergologist 1 (2.0)
Paediatrician 1 (2.0)
Paramedical specialty n (%) Mean (SD) Visits/mo
Physical therapist 43 (84.3) 7.4 (4.9)
Speech therapist 20 (40.0) 5.3 (2.3)
Psychomotor therapist 21 (45.7) 4.0 (1.8)
Psychologist 14 (32.6) 2.8 (1.4)
an = 47.
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help from volunteers or relatives. The remainder of re-
spondents said they did not need outside help, stating they
would look after their family and their home, in spite of
the situation “like everyone else”.
QoL scale results
Only 14 respondents (9 parents, 5 patients) completed the
KIDSCREEN-27 questionnaire, including 7 each from the
severe and attenuated groups. Parents were the respon-
dents for all 7 severe patients, while among the attenuated
respondents, 5 were patients and 2 were parents. The
KIDSCREEN-27 scores for the MPS II population were
consistently lower (worse) compared with the reference
control population for all 5 dimensions of the scale
(physical well-being, psychological well-being, auton-
omy and parents, peers and social support, and school
environment), regardless of age group and of whether
parents or patients were the respondents. Patient/parentscores generally ranged from 30 to 60, while reference
population scores ranged from 60 to 90, with median
scores usually in the 75 to 85 range, across all dimensions.
No individual patient/parent scores reached the reference
population median score for any dimension. The few in-
stances where individual respondent scores were within
the lowest quartile of the reference population scores oc-
curred with 1 patient respondent aged between 8–11 years
for the dimensions of autonomy and parents, and school
environment; 1 patient aged between 12–18 years for
peers and social support, and school environment, and
another patient in this age group for school environment;
and 2 parent scores, 1 for peers and social support, and
the other for school environment.
Five completed EQ-5D questionnaires were received
and analysed, all from adults answering for attenuated
patients; although 12 parents of severe patients responded
to the questionnaire, none completed all the questions.
Results for the EQ-5D VAS, which is for adults only and
covers 5 dimensions (mobility, autonomy, current activ-
ities, pain/discomfort, and anxiety/depression), were lower
than those for the reference population, as observed with
the KIDSCREEN-27. All total respondent EQ-5D scores
ranged from about 50 to 70, while reference population
scores ranged from approximately 75 to 90.
Support Services Utilization
Social services and financial support
Of 51 respondents, 37 (72.5%) reported they used a
social services assistant to help them with the adminis-
trative procedures required to request financial assist-
ance, or a home care aide, or to find a specialized facility
for patient care. Twelve (23.5%) respondents used the
services related to their Reference Center for Rare Dis-
ease, and 12 (23.5%) used services from schools and spe-
cialized centers.
Three quarters of 51 respondents (n = 39 [76.5%]) re-
ceived an education financial allowance for disabled chil-
dren (Allocation d’Education de l’Enfant Handicapé
[AEEH]), 15 (29.4%) received a disability living allowance
(Prestation de Compensation du Handicapé [PCH]), 6
adult patients received an adult disability allowance, and
2 (3.9%) received a compensatory allowance for a third
person (Allocation Compensatrice pour Tierce Personne
[ACTP]). Among the 39 families receiving the AEEH
benefits, 16 received no other aid, while 13 also received
PCH. In addition, 10 (19.6%) families received various
other types of financial aid. Only 3 families received no
financial aid.
Psychological counseling
Of the 51 respondents, only 7 (13.7%) indicated they had
received professional psychological counseling. Thirty-
seven (72.5%) were members of a patients’ association,
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somales; 5 were also members of another association.
The benefits of belonging to an association, according to
these respondents, included obtaining information, inter-
acting with other families/patients, social contact, making
useful contacts, obtaining help, listening, and support.Travel and other costs
Travel was one of the major costs for families. The dis-
tance traveled to centers for follow up evaluation and
medical treatment ranged widely, from < 20 kilometers
(km) for 10 (20.0%) patients to more than 700 km for 6
(12.0%) patients. The majority of patients (66.7%) used
their car or a taxi for these trips. The 19 (37.3%) families
who traveled more than 400 km, mainly represented pa-
tients who lived in the Southwest of France or Brittany
and used the center at Lyon for annual evaluation. This
helps explain why 7 (13.7%) families typically traveled by
airplane and 6 (11.8%) by train to the infusion centers.
The distance traveled for weekly infusions was 30 km
or less for the majority of families (65.6%), with only 1
patient needing to travel more than 100 km; 90.7% of
families used their car or a taxi for these trips.
Travel costs were reimbursed for 89.8% of patients,
although 13/52 (25.0%) families chose not to file for
reimbursements for short journeys made to medical and
paramedical appointments. Five families declined this
benefit entirely because they found the administrative
process too complicated and restrictive, and 3 had not
even thought of going through the process. Seventeen
families were reimbursed for beds, 9 families had paid
for travel to paramedical consultations and to the infusion
center, and 5 indicated that accommodations during tests
were an additional expense. Two families required trans-
port for a second adult to accompany them during tests,
and 2 families required travel to medical and educational
special needs facilities. Nine families indicated that they
had to pay for adaptations to their home or car.
One respondent indicated that hospital parking was an
additional cost. Other items listed as additional costs
paid by families included hearing aids, wheelchairs, and
non-reimbursable drugs.Choice of centers for follow up care
Twenty-seven (54.0%) patients had a choice of center for
follow up care. Notwithstanding the substantial travel
costs, only of 13 (48.1%) of these 27 based their choice
primarily on the proximity of the center to their home.
Other common criteria for the choice of follow up center
included a referral by a third party (29.4%), because it was
the center where the patient had been diagnosed (23.5%),
and familiarity with the medical staff at the follow up
center (25.9%), or with the center in general (18.5%),among others. Overall, 32 (62.7%) of 51 respondents
used different centers for follow up and infusion.
Idursulfase CGI-I and PGI-I results
CGI-I
Among all 52 patients, severe and attenuated combined,
44 (84.6%) reported that they were either “much im-
proved”, or “minimally improved”, 4 (7.7%) patients
showed “no change”, and 2 (3.8%) were judged “much
worse” during Period 1. For Period 2 (end of the first
year of treatment to the time of study evaluation),
among all patients, 24 (46.2%) were “very much im-
proved”, “much improved”, or “minimally improved”.
The 1 patient who was rated “very much improved” was
aged 8.5 years and had an attenuated form of MPS II. In
addition, 18 (34.6%) patients were rated “minimally
worse”, “much worse”, or “very much worse”, and 8
(15.4%) patients were rated unchanged.
Analysis of CGI-I scores by phenotype is shown in
Table 4. For Period 1, among the 33 severe patients,
93.9% were rated either improved (minimally-, much-,
or very much improved [n = 10; 30.3%]) or unchanged
(n = 21; 63.6%), while only 2 (6.1%) were minimally-,
much-, or very much worse. Of the 16 attenuated pa-
tients, all (100%) were either improved (n = 7; 43.8%) or
unchanged (n = 9; 56.3%). For Period 2, the majority of
severe patients (51.5%) were unchanged, while only 3
(9.1%) were improved and 13 (39.4%) were worse. Re-
sponse during Period 2 was more favorable among the
attenuated patients, with 7 (43.8%) patients rated as im-
proved, 7 (43.8%) rated as unchanged, and only 2 (6.1%)
rated as worse. Differences by age in CGI-I scores were
observed during Period 1, with mean (SD) age at start of
treatment being younger in severe patients who improved
compared with those who remained stable or worsened
(4.0 [1.6] versus 6.8 [5.3] and 6.9 [3.7] years, respectively)
and in attenuated patients who were improved or
remained stable (11.1 [6.6] versus 19.5 [13.0] years, re-
spectively). During Period 2, mean (SD) age at start of
treatment among severe patients was also younger for
those improved compared with those stable or worsened
(3.1 [2.8] versus 5.9 [5.9] and 6.2 [2.4] years, respectively).
Among attenuated patients, mean (SD) age was younger
in improved patients than in stable patients, but was also
younger in worsened than in stable patients (11.0 [7.8]
versus 21.6 [13.4] versus 12.6 [5.5] years, respectively).
Multivariate analysis showed no statistically significant re-
lationship between age at start of treatment or at diagnosis
and CGI-I scores for either Periods 1 or 2 and for either
phenotype, probably due to small sample sizes.
PGI-I
For Period 1, severe patients/caregivers gave highly posi-
tive PGI-I responses, with 54.0% stating they were either
Table 4 CGI-I results for patients with severe and attenuated phenotypes and for the total population for 2 time
periods
Severe (n = 33) Attenuated (n = 16) Total population
(N = 52)e
Period 1: From baseline
(ERT onset) versus 1 y later
n (%) Mean age at
start of ERT (y)
Mean age at
diagnosis (y)
n(%) Mean age at
start of ERT (y)
Mean age at
diagnosis (y)
N (%)
Significant improvementa 10 (30.3) 4.0 2.6 7 (43.8) 11.1 4.4 Improvementf 44 (84.6)
No change/little improvement
or worseningb
21 (63.6) 6.8 2.4 9 (56.2) 19.5 6.5 No change 4 (7.7)
Significant worseningc 2 (6.1) 6.9 2.7 0 (0) – – Worseningg 2 (3.8)
P valued 0.1181 0.9448 0.1248 0.2235
Period 2: From end of first
year ERT versus present
n (%) Mean age at
start of ERT (y)
Mean age at
diagnosis (y)
n (%) Mean age at
start of ERT (y)
Mean age at
diagnosis (y)
Significant improvementa 3 (9.1) 3.1 2.1 7 (43.8) 11.0 4.9 Improvementf 24 (46.2)
No change/little improvement
or worseningb
17 (51.5) 5.9 2.7 7 (43.8) 21.6 6.8 No change 8 (15.4)
Significant worseningc 13 (39.4) 6.2 1.7 2 (12.5) 12.6 3.7 Worseningg 18 (34.6)
P valued 0.2619 0.0638 0.1710 0.6233
a“Very much improved” and “much improved”.
b“Minimally improved”, “no change”, and “minimally worse”.
c“Much worse” and “very much worse”.
dWilcoxon test.
eTwo patients in the total population were not evaluable each during Period 1 and Period 2.
f“Very much improved”, “much improved”, and “minimally improved”.
g“Minimally worse”, “much worse”, “very much worse”.
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while 28.0% said they were “minimally improved”; 6.0%
were unchanged and 3.0% each were much worse or very
much worse (Figure 1). Among the attenuated patients/
caregivers, the PGI-I responses for Period 1 were also
strongly positive, with 50.0% stating they were either very
much improved (12.5%) or much improved (37.5%), while
37.5% said they were minimally improved and 12.5% were
unchanged; no attenuated patients/caregivers said the
condition had worsened. For Period 2, the PGI-I ratings
were somewhat less positive, with the greatest percent-
age of severe patients/caregivers (37.0%) rating the
patient’s condition as unchanged (Figure 2). However,
one-third (33.0%) of the severe cohort still rated them-
selves/the patient as very much improved (3.0%), much
improved (9.0%), or minimally improved (21.0%); 12.0%
of severe patients were rated worsened compared with
6% during Period 1. Among attenuated patients, most
patients/caregivers (62.0%) rated themselves/the patients as
either minimally improved (31.0%) or unchanged (31.0%);
31.0% were rated very much improved (6.0%) or much
improved (25.0%), and 6.0% were worsened, compared
with 0% during Period 1.
Discussion and conclusions
This study gathered broad data on the impact and burden
of MPS II, the organization and efficiency of clinical
management for this disease, and the benefits of ERT
for MPS II, in France. The study included 52 patientsbeing treated with idursulfase, representing 83.9% of all
such eligible patients that had been identified at French
Reference Centers for Metabolic and Lysosomal Dis-
eases. The patients represented a wide range of ages
(from 1 year to 51 years), and the majority (69.2%) had a
severe phenotype, which is consistent with other epide-
miologic estimates of about two-thirds of patients with
the severe phenotype in sample MPS II populations at
any given point in time [2]; however, the higher mortal-
ity rates of severe relative to attenuated patients may
render such prevalence estimates considerably variable.
It should also be noted that as respondents were asked
to recollect current and historical data, the likelihood of
recall bias cannot be eliminated.
In this trial, we chose to include only treated MPS II
patients. At first glance, this may appear as a major
weakness of the study; however, at the time of the study,
as therapy was available commercially in France, the
number of untreated patients was extremely limited and
most of them were at a very advanced stage of the disease,
some of them being also under palliative care. Given this
setting, it appeared that including untreated patients as a
comparison group would have introduced a greater degree
of bias into the study than excluding them. It seems likely
that if all patients with MPS II had been included in the
study then the burden of disease may have been recorded
as being greater than is shown here.
The well-known, multisystemic disease manifestations
and problems associated with MPS II were represented
Figure 1 Comparison of the CGI-I and PGI-I responses for patients
with severe and attenuated forms of MPS II for Period 1 (from be-
fore ERT to after 1 y of treatment). Severe PGI-I: n = 33, CGI-I: n = 33.
Attenuated PGI-I: n = 16, CGI-I: n = 16.
Figure 2 Comparison of the CGI-I and PGI-I responses for patients
with severe and attenuated forms of MPS II for Period 2 (1 y after
start of ERT to presenta). Severe PGI-I: n = 33, CGI-I: n = 33. Attenuated
PGI-I: n = 16, CGI-I: n = 16. aFinal measurements taken January 31, 2012.
Period from end of the first year of treatment to the present varied
among patients but was >2 years.
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severe and attenuated patients had experienced hearing
loss, disabling joint stiffness, hernia, and adenoidectomy
at the time of the study. The frequency of various
medical conditions among the attenuated patients, in
some cases exceeding that in the severe group, may be
explained by the greater time since diagnosis and the
older ages of the attenuated patients. Hence, despite the
clear differences between the phenotypes, these data
also illustrate how attenuated patients can ultimately be
as greatly affected as severe patients by many of the
somatic disease manifestations of MPS II over their
longer life spans. Although cognitive impairment is
more commonly associated with the severe phenotype
[2,3], 4 (25.0%) patients with the attenuated phenotypehad experienced mild mental retardation without re-
gression, and about 80% of both severe and attenuated
patients had experienced at least 1 surgical intervention.
Difficulties in clinical management of MPS II were also
apparent from these data. A family history of MPS II was
ultimately found to be present in 17 (32.7%) patients,
although only 1 prenatal diagnosis had been performed.
However, the majority of parents and patients did not
know of the existing MPS II cases in their family at the
time of diagnosis and these family histories were only
discovered retrospectively. The majority of patients did
not know of the existing MPS II cases in their family.
Identification of (and commensurate attention to) first
symptoms was more commonly made by parents (49.0%
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tor (13.7% of cases), which may indicate a need for better
education in recognition of the signs and symptoms of
MPS II among paediatrician and family doctors. Indeed,
about 40% of patients had to wait from 7 to 20 years for a
diagnosis following the initial observation and documenta-
tion of symptoms, and 9 (17.6%) patients/families had to
see from 5 to 8 physicians. Although data are lacking on
rates of recognition of MPS II among clinicians, it has
been noted that expertise in diagnosis and management of
MPS II varies between countries in Europe [20]. In
addition, 40% of respondents felt the diagnosis, when de-
livered, was given in a façon brutale or brutal way, and
psychological support was offered at the time of diagnosis
to only 28.0% of respondents. Finally, only half of respon-
dents felt that they had received clear information about
the disease upon diagnosis from the diagnosing physician.
Overall, the survey data on detection and diagnosis of
MPS II suggest more should be done to disseminate
knowledge of this rare disease among clinicians and thus
facilitate rapid and compassionate diagnosis, and timely
treatment.
Twenty-two out of 33 patients reported they received
idursulfase “immediately” after diagnosis. We consider
this a positive feature of the French healthcare system,
which allows initiation of ERT in the weeks following
MPS II diagnosis. Infusions were the most commonly
administered at hospital (62.7%), while only 4 (7.8%)
patients were treated at home under the HAD program,
although 64.0% of patients/families said they would like
to receive home infusions. Home infusion cannot be per-
formed in France unless a hospital facility provides the
drug and infusion. The majority of families who decided
against home infusion, however, said they found hospital
care reassuring. A potential bias is that patients on home
therapy may see a physician less frequently, so potential
complications may be detected less promptly, in com-
parison with those patients seen frequently in hospital
settings. This might lead to an improvement in per-
ceived QoL over and above that of idursulfase treatment
for those in a hospital setting. On the other hand, pa-
tients who are able to receive ERT at home are likely to
be more stabilized, so this may help counter this bias.
The authors believe; however, that disease evaluation
and treatment in France is essentially the same, whether
patients receive ERT in hospital or at home, and that
therefore improved QoL is unlikely to be linked to the
site of administration of ERT.
The impact of MPS II on patient/family QoL came out
in responses to the patient/parent questionnaire and the
results of the KIDSCREEN-27 and EQ-5D scales. Close
to half of parents (45.5%) had to reorganize their work-
ing hours to accommodate patients care, and about
one-fifth (22.7%) had to stop working. Choice of place tolive was affected for 4 families, and many families had
either obtained paid household help (15.7%) or were re-
ceiving regular help from volunteers or relatives (35.3%).
The many, diverse demands of MPS II for healthcare, as
listed in Table 3 (i.e., hospital, medical specialist, and
paramedical specialist visits and services), suggest some
of the likely reasons for these lifestyle adjustments. How-
ever, approximately half of the families were willing to
manage their needs without seeking household help. On
both the KIDSCREEN-27 and the EQ-5D scales, respond-
ent scores were well below median reference population
scores across all dimensions and age groups of respon-
dents. The mean total EQ-5D scores ranged from 5 to
40 VAS units lower than those of the reference popula-
tion; the minimally important difference for the EQ-5D
VAS has been estimated to range from 7–12 [21]. In a
recent study, Raluy-Callado et al. showed, using a number
of validated patient and caregiver questionnaires, that
MPS II patients with the attenuated phenotype generally
score consistently lower than paediatric subjects with type
1 diabetes, juvenile idiopathic arthritis, asthma, or atten-
tion deficit disorder [4]. Physical function and the ability
to perform day-to-day activities were the most affected
areas in a group of patients when compared with normal
paediatric populations. Health-related QoL issues were
also impacted by the disease, particularly the psychological
aspects such as self-esteem and family cohesion, where
the subjects scored even lower than those for physical
function. This emphasis on the impact of the disease on
caregivers and families, in particular, agrees with the
findings from this study. Likewise, the hearing loss
experienced by 80.0% of the patients in this study is in
agreement with previous work [21,22]. Although the
KIDSCREEN-27 and EQ-5D results suggest that the
QoL of patients with MPS II is lower than the reference
population, the number of respondents was low, and
definitive conclusions cannot be reached from these
QoL measures in this study. The authors’ experience is
that KIDSCREEN-27, in particular, is not well adapted
to assessing patients with severe MPS II.
Use of social and financial support benefits was exten-
sive. Almost all families received some form of financial
support, most commonly (76.5%) the education allow-
ance for disabled children (AEEH) available in France;
only 3 families received no financial support. Many also
received social services support (72.5%), mostly to help
with financial aid (73.0%) and social service paperwork
(86.5%). This level of support demonstrates how much
these patients benefit from healthcare support in France,
particularly when compared with many other countries.
Travel costs and accommodations during tests were
also a substantial financial burden for families, for
which they often did not seek reimbursement either
out of choice or because they found the application
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of families in coping with the burden of MPS II, and the
social structures available to help them, suggest that more
can be done to increase the number of patients receiving
home infusion, which was a preferred option for most
patients/families and could also decrease travel costs.
Better access to educational and other social facilities for
children is also needed for MPS II patients.
With regard to response to treatment, the CGI-I ques-
tionnaires showed that after the first year of ERT (Period
1), 93.9% of severe patients were either improved (n = 10;
30.3%) or stabilized (n = 21; 63.6%), while only 2 (6.1%)
worsened, and all 16 attenuated patients showed either
improvement (n = 7; 43.8%) or stabilization (n = 9; 56.3%)
(Table 4). Among patients with either phenotype, the best
improvement was observed in patients with the youngest
mean (SD) age at the start of ERT (Table 4). Further im-
provement during Period 2 (from the end of the first
year of ERT to the present) was seen by clinicians in 3
(9.0%) severe patients, while 51.5% were stable and
39.4% worsened; as in Period 1, the improved severe
patients had a younger mean age than stable or worsened
patients. These results are consistent with the natural
history and progression of MPS II in severe patients.
Among attenuated patients, 87.6% were either improved
(n = 7; 43.8%) or stable (n = 7; 43.8%) after Period 2,
while only 2 were worse, for reasons which were not
specified but could have been related to factors beyond
treatment effect (e.g., neurosurgery). Overall, given the
progressive nature of MPS II, particularly in severe
patients, it is clinically significant and could be regarded
as beneficial that 9.1% of severe patients and 43.8% of
attenuated patients manifested CGI-I improvement in
status during Period 2, after a mean of 3.8 ± 1.3 years of
ERT. The multivariate analysis showing neither age at
diagnosis nor age at the start of idursulfase treatment was
associated with CGI-I ratings, among both severe and at-
tenuated patients, and during both treatment periods, was
surprising since MPS II is generally less responsive to
treatment after disease progression, but this may be due to
insufficiently large sample sizes. Nonetheless, the nonsig-
nificant associations of younger age with better response
to ERT are consistent with our previous experience that
this treatment is most effective for somatic problems at
earlier rather than late stages of progression.
The disparities between the PGI-I and CGI-I ratings
during both Periods 1 and 2, shown in Figures 1 and 2,
are also notable. In the severe group, the percent of
patients/parents rating the patient “very much improved”
or “much improved” during Period 1 was almost double
that of clinicians giving these ratings (55.0% combined
ratings versus 30.3% combined ratings, respectively).
Perhaps a placebo effect influenced this result. Conversely,
in the attenuated group, more clinicians than patients/caregivers rated the patients “much improved” or “minim-
ally improved” (44.0% and 56.0% versus 38.0% for each
rating, respectively) for Period 1; it could be that the clini-
cians had a more positive view than the patients because
they tend to compare them with the more rapid disease
progression of the severe phenotype. In addition, the
patients may experience treatment-related burdens that
give them a more negative impression of their condi-
tion. However, 13.0% of PGI-I ratings for Period 1 were
“very much improved” compared with 0% of CGI-I
ratings for the same period, which could also indicate a
placebo effect for some patients. For Period 2, the CGI-I
and PGI-I ratings were somewhat more consistent with
each other; however, more than twice the percentages
of patients/caregivers rated the patient as unchanged
in both the severe and attenuated groups versus the
clinician ratings, and more clinicians than patients/
caregivers saw worsening in the patients during this
period. Overall, it must be noted for both the CGI-I and
PGI-I that the ratings for Period 1 were given retro-
spectively since most patients had been receiving treat-
ment for several years (mean 3.8 years), introducing a
bias of perspective from the present time to the first-
year period. In addition, the treatment intervals differ
for each patient, which could further influence the rat-
ings. Therefore, given the variability of patient factors
and treatment conditions from which these retrospect-
ive, observational data were drawn, the study results
must be interpreted with caution.
Drawn from a “real-world” clinic sample, this study adds
to the increasing knowledge about the characteristics and
burden of MPS II, its clinical management in France, and
the effects of idursulfase treatment from both the clinician
and patient perspectives. It was the intention of this study,
and it is the aspiration of the authors, that these data help
to clarify the full burden of MPS II on patients and their
families, and also to identify areas for improvement in the
clinical management of this disease and in providing
support for families in coping with it.
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